STAT6¹¹ STAT6
Signal Transducer and Activator of Transcription 6 — the transcription factor activated downstream of both IL-4 and IL-13 receptor signaling, translating Th2 cytokine input into gene expression changes in target tissues sits at the convergence of the allergic inflammation circuit. When IL-4 or IL-13 binds their shared receptor subunit (IL-4Rα), JAK kinases phosphorylate STAT6, enabling it to dimerize and translocate to the nucleus, where it drives expression of IgE class-switching factors, mucus genes, and eosinophil-recruiting chemokines. Every atopic tissue — asthmatic airways, eczematous skin, inflamed esophageal epithelium — shows STAT6 activation as a central event.

The rs12368672 variant lies deep within an intron of STAT6 on chromosome 12q13.3, roughly 18 kb into the gene's reference sequence. The C allele is ancestral and more common (~68% globally); the G allele reaches highest frequency in Europeans (~40%) and lowest in Africans (~18%). Three STAT6 intronic variants — rs324011, rs167769, and rs12368672 — form a tight linkage disequilibrium block (r² ≥ 0.80), meaning they are typically inherited together as a haplotype and studies of any one serve as proxies for the others.

The Mechanism

As a deep intronic variant, rs12368672 does not alter the STAT6 protein sequence. Its most likely functional modes are [cis-regulatory | affecting gene expression from the same chromosome copy] — influencing STAT6 transcription levels, pre-mRNA splicing efficiency, or RNA stability in specific tissues. In tissues activated by IL-13 (esophageal epithelium, bronchial mucosa, intestinal epithelium), even modest differences in STAT6 expression or transcript processing could alter the gain of the IL-4/IL-13 → STAT6 signaling axis. The closely linked rs324013 variant in the same STAT6 LD block has been shown by electrophoretic mobility shift assay to affect transcription factor binding at its locus²² affect transcription factor binding at its locus
He et al., Genes Immun 2008, suggesting the haplotype has genuine regulatory effects on STAT6 expression rather than being a purely neutral tag.

When STAT6 is expressed at higher levels or is more efficiently activated, the downstream consequences in Th2-activated tissues include enhanced eosinophil recruitment (via eotaxin/CCL26 upregulation), increased goblet cell mucin production, and amplified epithelial barrier disruption — the cellular substrate of eosinophilic esophagitis, atopic asthma, and atopic dermatitis.

The Evidence

The most direct evidence for rs12368672 comes from a 2021 prospective cohort study of 73 pediatric eosinophilic esophagitis patients by Mougey et al.³³ 2021 prospective cohort study of 73 pediatric eosinophilic esophagitis patients by Mougey et al. All three STAT6 LD-block variants (rs324011, rs167769, rs12368672) were genotyped; carriers of the G-allele haplotype faced 2.3- to 2.8-fold increased odds of EoE relapse after one year of maintenance proton pump inhibitor (PPI) therapy (OR 2.77, 95% CI 1.11–6.92 for rs324011; P = .029). Carriers also faced 2.8- to 4.1-fold increased odds of intermediate-grade tissue eosinophilia (6–14 eos/hpf, a marker of incomplete remission). This is the only study with direct genotype-outcome data for rs12368672 itself; effect sizes were consistent across all three linked variants.

A 2024 pharmacogenetic study of 28 EoE patients by Soria-Chacartegui et al.⁴⁴ 2024 pharmacogenetic study of 28 EoE patients by Soria-Chacartegui et al. specifically examined rs12368672 genotype and found that GG homozygotes had significantly higher baseline peak eosinophil counts compared to G/C and C/C carriers (83.2 vs 52.9 eos/hpf; P = 0.027). GG and GC genotypes showed greater EREFS symptom score reduction with omeprazole, suggesting the G allele enriches a subset of EoE patients who are more responsive to PPI-mediated STAT6 suppression — but who also relapse more rapidly without it.

For asthma, a 2023 Chinese case-control study (Zheng et al., 597 asthma cases / 632 controls) found significant differences in rs12368672 genotype and allele distributions between asthma patients and healthy controls⁵⁵ 2023 Chinese case-control study (Zheng et al., 597 asthma cases / 632 controls) found significant differences in rs12368672 genotype and allele distributions between asthma patients and healthy controls (P = 0.007), supporting a shared genetic susceptibility role for the STAT6 LD block across atopic airway conditions.

In the context of parasite defense, the linked rs324013 variant in the same STAT6 region showed an additive interaction with IL13 rs1800925 on urinary schistosome infection burden in an 841-person Malian cohort⁶⁶ an additive interaction with IL13 rs1800925 on urinary schistosome infection burden in an 841-person Malian cohort — each variant alone was associated with infection levels, and carrying risk alleles at both loci compounded the susceptibility (additive interaction P = 0.011). This documents that the STAT6 LD block regulates Th2-mediated parasite defense as well as allergic tissue eosinophilia, two sides of the same Th2 immune coin.

Practical Actions

For G-allele carriers, the actionable implications center on the esophageal and airway phenotypes where STAT6 pathway activation drives eosinophil-mediated tissue damage. In EoE, the G allele signals elevated relapse risk on maintenance PPI therapy, making endoscopic follow-up during PPI dose reduction a specific and genotype-relevant monitoring step. For asthma or atopic disease generally, STAT6-pathway biologics (dupilumab blocks IL-4Rα upstream of STAT6; a number of downstream targets are also in development) are particularly relevant for patients with poor control.

Interactions

The primary interaction partner for this variant is [rs1800925 | IL13 -1112C>T promoter variant — the T allele increases IL-13 production in Th2 cells by disrupting a STAT6 repressor binding site and creating a Yin-Yang 1 activator site], whose risk T allele increases the ligand load on the STAT6 pathway. Carrying both the IL13 -1112T allele (more IL-13 produced) and the STAT6 G-allele haplotype (altered STAT6 expression) places both ends of the IL-13 → STAT6 signaling axis in a sensitized state. The He et al. (2008) data on schistosome infection demonstrates a statistically significant additive interaction (P = 0.011) between these variants at exactly this junction.

The [rs1801275 | IL4R Q576R (rs1801275-G) — gain-of-function variant in the IL-4Rα receptor subunit upstream of STAT6] is another relevant partner: a hyperactive IL-4Rα receptor would further amplify STAT6 signaling even if STAT6 expression is unaltered, compounding a STAT6 regulatory variant's effect.

CD33 (Siglec-3)¹¹ CD33 (Siglec-3)
A sialic acid-binding immunoreceptor expressed on myeloid cells including microglia; member of the Siglec family that inhibits cellular activation through ITIM signaling domains is expressed abundantly on microglia, the brain's resident immune cells and primary clearers of amyloid-beta plaques. In Alzheimer's disease, microglia fail to efficiently engulf and degrade amyloid deposits — and CD33 is a key molecular brake on that process. The rs12459419 variant sits in exon 2 of CD33 and fundamentally changes how much of this brake is active in your microglia.

The Mechanism

CD33 exists in two functional isoforms determined by alternative splicing of exon 2. The full-length isoform (FL-CD33) contains the IgV domain²² IgV domain
The immunoglobulin V-set domain encoded by exon 2; responsible for binding sialic acid residues on adjacent cells; required for CD33's inhibitory signaling through ITIM motifs — a sialic acid-binding domain that allows CD33 to suppress microglial phagocytic activity via ITIM-mediated signaling. The short isoform (D2-CD33), produced when exon 2 is skipped during splicing, lacks this IgV domain entirely. Without the inhibitory domain, microglia carrying D2-CD33 are more active phagocytes — they internalize and degrade amyloid-beta more efficiently.

The rs12459419 T allele promotes exon 2 skipping, shifting the splicing balance toward more D2-CD33 transcript relative to FL-CD33. Each copy of the T allele reduces full-length CD33 expression by approximately 25%³³ Each copy of the T allele reduces full-length CD33 expression by approximately 25%
Measured by qPCR of brain tissue and flow cytometry of peripheral monocytes in human samples stratified by rs12459419 genotype, raising the proportion of the phagocytosis-competent short isoform. The protective effect is additive: TT homozygotes have the greatest exon 2 skipping, CT heterozygotes intermediate, and CC homozygotes the least — maintaining the maximum inhibitory CD33 brake on microglial clearance activity.

The Evidence

The rs12459419 T allele was identified as the likely causal variant for the CD33 Alzheimer's GWAS signal originally detected at the promoter SNP rs3865444⁴⁴ rs3865444
Located ~515 bp upstream of the rs12459419 coding position; identified as an AD GWAS hit in multiple large studies but likely acts through LD with the functional exon 2 splicing variant. The two SNPs are in high linkage disequilibrium; fine-mapping experiments suggest rs12459419 is the causal functional change.

Alzheimer's disease protection: Malik et al. 2015⁵⁵ Malik et al. 2015
Human Molecular Genetics, multi-cohort analysis found that each T allele copy reduced the Alzheimer's disease odds ratio by approximately 0.10 per allele, with TT homozygotes showing the greatest protection. The effect is consistent across multiple independent cohorts and is biologically coherent: more exon 2 skipping → less FL-CD33 → less inhibition of microglial phagocytosis → more efficient amyloid clearance.

Direct functional validation: Bhattacherjee et al. 2021⁶⁶ Bhattacherjee et al. 2021
Molecular Neurodegeneration, PMID 33766097 demonstrated directly that the D2-CD33 isoform (the exon 2-skipped form) is a gain-of-function variant for microglial phagocytosis — microglia expressing D2-CD33 show significantly enhanced uptake of Aβ(1-42) compared to cells expressing full-length CD33. This makes rs12459419 one of the few Alzheimer's risk variants with a clear and directly demonstrated protective mechanism.

Evolutionary context: Schwarz et al. 2016⁷⁷ Schwarz et al. 2016
PNAS showed that the rs12459419 T allele and exon 2 skipping are evolutionarily derived, human-specific traits (absent in other great apes), and are associated with protection against post-reproductive cognitive decline. This evolutionary framing suggests the exon 2 splicing variant emerged specifically in the human lineage, possibly as an adaptation supporting longer cognitive health.

AML pharmacogenomics: The same rs12459419 T allele that reduces CD33 surface expression also determines response to gemtuzumab ozogamicin (Mylotarg), a CD33-targeting antibody–drug conjugate used in acute myeloid leukemia. CC homozygotes express more surface CD33 and respond better to gemtuzumab; TT homozygotes have lower CD33 surface density and may have reduced response. Lamba et al. 2017⁸⁸ Lamba et al. 2017
Journal of Clinical Oncology established rs12459419 as a predictive biomarker for gemtuzumab ozogamicin response — an independent clinical significance domain beyond Alzheimer's.

Practical Implications

For most people, this variant's primary relevance is Alzheimer's disease risk modification — specifically, whether your microglia are more or less capable of clearing amyloid-beta. The T allele confers measurable protection, but it is not a guarantee against Alzheimer's nor does its absence guarantee disease. APOE ε4 status, lifestyle factors, and numerous other genetic variants interact to shape overall risk.

For T allele carriers, the beneficial mechanism — enhanced microglial phagocytosis — can be further supported through strategies that maintain microglial function: omega-3 DHA adequacy (a key component of microglial membranes and phagocytic capacity) and management of factors known to impair microglial activity such as chronic neuroinflammation from metabolic syndrome or sleep apnea. For CC carriers (the modal genotype), monitoring cognitive health and addressing modifiable Alzheimer's risk factors earlier takes on added relevance given the reduced microglial phagocytic reserve.

Interactions

Rs12459419 is in high linkage disequilibrium with rs3865444, a promoter variant that was the original CD33 Alzheimer's GWAS signal. The two variants are typically co-inherited and fine-mapping suggests rs12459419 is the causal variant driving the GWAS association through splicing effects, while rs3865444 may contribute independently through altered CD33 promoter activity. In practice, most users will share the same allele pattern at both loci.

The CD33 phagocytosis pathway intersects with other microglial function genes implicated in Alzheimer's risk: TREM2, BIN1, CLU, CR1, and PICALM all converge on microglial amyloid handling. Individuals carrying both the CD33 CC risk genotype and TREM2 risk variants (e.g. rs75932628, R47H) would have two independent deficits in microglial amyloid clearance — a potential compound interaction worth noting.

PPARG (Peroxisome Proliferator-Activated Receptor Gamma¹¹ Peroxisome Proliferator-Activated Receptor Gamma
A nuclear receptor that acts as the master transcription factor controlling adipocyte differentiation and lipid storage; it is also the pharmacological target of the thiazolidinedione class of insulin-sensitizing diabetes drugs) is one of the most clinically relevant metabolic genes in the human genome. It controls whether stem cells become fat cells, how efficiently adipose tissue stores and releases lipids, and how sensitively peripheral tissues respond to insulin. rs12636454 is an intronic variant within PPARG — it lies within the gene's non-coding sequence and does not change the protein — but large tagSNP studies have associated it with modest differences in type 2 diabetes risk.

The Mechanism

Intronic variants can influence gene expression through several routes: altering enhancer elements within introns, affecting RNA splicing efficiency, or acting as linkage disequilibrium²² linkage disequilibrium
LD — the tendency of nearby variants to be inherited together, so an intronic variant can serve as a marker for a functional variant elsewhere in the region that has not been separately catalogued proxies for untyped functional variants elsewhere in the PPARG locus. For rs12636454, no specific molecular mechanism has been identified in published literature. Its biological relevance rests on being embedded within PPARG — a gene whose reduced transcriptional activity is associated with improved insulin sensitivity — and on its statistical association with T2D risk in a well-powered cohort study.

PPARG governs adipogenesis at the master-regulator level: it transcriptionally activates hundreds of target genes required for fat-cell differentiation, lipid uptake, and fatty acid esterification. Paradoxically, variants that slightly reduce PPARG activity (such as the well-established Pro12Ala missense variant at the same gene) are associated with improved insulin sensitivity, likely because excessive PPARG-driven fat storage in visceral adipose tissue contributes to ectopic lipid deposition and systemic insulin resistance. Whether rs12636454 influences PPARG expression levels or splicing has not been established by published functional data.

The Evidence

The primary evidence comes from a case-control study nested in the Women's Health Initiative³³ case-control study nested in the Women's Health Initiative
Chan et al. Common genetic variants in peroxisome proliferator-activated receptor-γ (PPARG) and type 2 diabetes risk among Women's Health Initiative postmenopausal women. J Clin Endocrinol Metab, 2013, involving 1,543 T2D cases and 2,170 matched controls. Twenty-four PPARG tagSNPs were assessed by multivariable logistic regression. rs12636454 was among five promoter-region variants showing statistically significant association with reduced T2D risk (odds ratios 0.68–0.78, p ≤ 0.05), with rs9817428 from that group also replicating in a separate cohort of 5,642 African American and Hispanic American women. The individual OR and confidence interval for rs12636454 alone was not separately reported; the effect estimate reflects the range across the five-variant group.

Genome-scale mechanistic work by the MAGIC Investigators⁴⁴ MAGIC Investigators
Dimas et al. Impact of type 2 diabetes susceptibility variants on quantitative glycemic traits reveals mechanistic heterogeneity. Diabetes, 2014 classified PPARG as one of four loci whose T2D effect operates primarily through insulin sensitivity (fasting insulin levels) rather than insulin secretion — alongside KLF14, IRS1, and GCKR. This cluster-level classification, based on 58,614 nondiabetic subjects, establishes the mechanistic context: variation in this gene region influences how effectively peripheral tissues respond to circulating insulin.

The evidence level for rs12636454 specifically is rated emerging: it derives from a single study in postmenopausal women, the OR is reported as a group estimate rather than variant-specific, and no independent replication has been published for this exact rsid. The PPARG gene-level evidence (from Pro12Ala and the locus overall) is substantially stronger and well-established.

Practical Implications

Because the mechanism of PPARG-region variants is insulin sensitivity — not insulin secretion or pancreatic beta-cell function — the most targeted interventions are those that reduce demands on insulin signaling and support adipose tissue health. Dietary fat quality matters specifically for PPARG carriers: omega-3 polyunsaturated fatty acids (EPA and DHA) have been shown to activate PPARγ and upregulate glucose transporters⁵⁵ activate PPARγ and upregulate glucose transporters
González-Périz et al. Obesity-induced insulin resistance and hepatic steatosis are alleviated by omega-3 fatty acids. FASEB J, 2009 GLUT-2 and GLUT-4, with downstream lipid mediators (resolvins, protectins) producing effects comparable to thiazolidinedione drugs. This gene-nutrient interaction is specific to the PPARG pathway and makes omega-3 intake mechanistically relevant for this genotype.

For carriers with T2D or prediabetes who eventually require pharmacological treatment, thiazolidinedines (pioglitazone) directly target PPARG. A meta-analysis of 777 patients⁶⁶ meta-analysis of 777 patients
Jang et al. Correlation between PPARG Pro12Ala Polymorphism and Therapeutic Responses to Thiazolidinediones in Patients with T2D. Pharmaceutics, 2023 found that PPARG Ala12 carriers achieved 0.3% greater HbA1c reduction and ~11 mg/dL greater fasting glucose reduction on pioglitazone or rosiglitazone than Pro12 homozygotes. While that pharmacogenomic finding is for the Pro12Ala coding variant, it establishes PPARG as a gene where variation predicts differential drug response — a clinically actionable context for rs12636454 carriers facing T2D treatment decisions.

Interactions

rs12636454 is located in the same PPARG gene as rs1801282 (Pro12Ala), which has established evidence for insulin sensitivity effects. The two variants are likely in moderate linkage disequilibrium within the gene, but they are not redundant: Pro12Ala is a coding missense with a known molecular mechanism (reduced transcriptional activity of PPARγ2 isoform), while rs12636454 is intronic with an unknown functional mechanism. Their combined effect on PPARG expression or activity has not been studied. In the broader insulin sensitivity pathway, PPARG variants compound with IRS1 and KLF14 loci — all classified in the same mechanistic cluster in the MAGIC consortium data.

CYP2C8 is the liver's primary enzyme for metabolizing paclitaxel¹¹ paclitaxel
paclitaxel: a widely-used taxane chemotherapy drug for breast, ovarian, and lung cancers and its newer cousin [cabazitaxel | cabazitaxel: a second-generation taxane used in castration-resistant prostate cancer after docetaxel failure]. It is also responsible for clearing rosiglitazone and pioglitazone (thiazolidinedione diabetes drugs), repaglinide (a short-acting insulin secretagogue), and the anti-malarial amodiaquine. Beyond drug metabolism, CYP2C8 converts arachidonic acid into [epoxyeicosatrienoic acids (EETs) | EETs: potent vasodilatory and anti-inflammatory lipid mediators with cardioprotective and neuroprotective effects], making it a dual-purpose enzyme in both pharmacology and endogenous lipid signaling.

The rs1341164 variant lies within an intron of CYP2C8 — it does not change any amino acid — but intronic SNPs can still matter by tagging haplotype blocks that alter splicing efficiency, mRNA stability, or transcription factor binding sites. The evidence for rs1341164 is currently emerging: a single pharmacogenomic study has directly tested it, and the broader *IG haplotype literature provides indirect mechanistic context.

The Mechanism

rs1341164 is located at chromosome 10, position 95,041,116 (GRCh38), in intron 8/9 of CYP2C8 (HGVS: NC_000010.11:g.95041116T>C). As a C allele carrier, you may be tagging a haplotype group with reduced CYP2C8 expression or catalytic efficiency. The *IG haplotype study by Saito et al.²² *IG haplotype study by Saito et al.
Saito Y et al. CYP2C8 haplotype structures and their influence on pharmacokinetics of paclitaxel in a Japanese population. Pharmacogenet Genomics, 2007 found that CYP2C8 haplotypes harboring several intronic variations were associated with a 2.5-fold higher area under the curve (AUC) of the major paclitaxel metabolite 6α-hydroxypaclitaxel, consistent with reduced CYP2C8 clearance. Whether rs1341164 is a tag SNP for this haplotype group has not been formally confirmed.

The Evidence

The most direct evidence comes from a 2022 pharmacogenomics study of metastatic castration-resistant prostate cancer (mCRPC). Herrero Rivera et al.³³ Herrero Rivera et al.
Herrero Rivera D et al. Single-nucleotide polymorphism associations with efficacy and toxicity in metastatic castration-resistant prostate cancer treated with cabazitaxel. Pharmacogenomics, 2022 analyzed 56 SNPs across five drug-metabolism genes in 67 cabazitaxel-treated patients and found that rs1341164 C allele carriers had significantly better overall survival (hazard ratio 0.53 in multivariate analysis). The most plausible interpretation is that C allele carriers clear cabazitaxel more slowly, resulting in higher drug exposure and better tumor kill — consistent with the *IG haplotype's reduced clearance phenotype.

Parallel evidence exists for paclitaxel: Hertz et al.⁴⁴ Hertz et al.
Hertz DL et al. Genetic heterogeneity beyond CYP2C8*3 does not explain differential sensitivity to paclitaxel-induced neuropathy. Breast Cancer Res Treat, 2014 demonstrated in 412 breast cancer patients that CYP2C8 low-metabolizer status (combined *2, *3, *4 variants) increased peripheral neuropathy risk by 72% (HR 1.722, p=0.018). This raises the possibility that rs1341164 C-allele carriers — if they indeed clear paclitaxel more slowly — may face similar neurotoxicity risk, though this has not been directly studied.

Important caveat: The cabazitaxel study was small (n=67) and the authors explicitly described results as "hypothesis-generating." rs1341164 has no entry in ClinVar, no CPIC or DPWG guideline, and has not been replicated. The evidence level is emerging.

Practical Actions

The principal clinical implication is in taxane chemotherapy contexts (paclitaxel, docetaxel, cabazitaxel). If you carry the C allele and your oncologist is prescribing a taxane, this variant warrants discussion — not because it mandates dose changes, but because it may contribute to your overall CYP2C8 metabolizer phenotype. Formal pharmacogenomic testing using a certified panel (which covers the clinically established *2, *3, *4 alleles alongside less-characterized intronic variants) provides a more complete picture.

The EET-production aspect of CYP2C8 function is also relevant: since EETs are cardioprotective and vasodilatory, variants that alter CYP2C8 expression in vascular endothelium may modulate cardiovascular risk — though this pathway has not been directly studied for rs1341164.

Interactions

CYP2C8 activity interacts with CYP2C9 (encoded by the adjacent gene on chromosome 10q24.1) — inhibitors of one often affect the other. CYP2C8 is potently inhibited by gemfibrozil (a lipid-lowering drug), which can increase exposure to repaglinide by up to 8-fold; this interaction does not depend on rs1341164 genotype but is relevant context when CYP2C8 metabolizer phenotype is uncertain. For the EET pathway, rs1341164 may interact with soluble epoxide hydrolase (EPHX2) variants: CYP2C8 makes EETs and EPHX2 degrades them, so reduced CYP2C8 combined with reduced EPHX2 activity may alter EET balance in a cardiovascular-relevant direction.

CYP7A1¹¹ CYP7A1
Cytochrome P450 family 7, subfamily A, member 1 — encodes cholesterol 7α-hydroxylase, the rate-limiting enzyme converting cholesterol to bile acids in the liver controls the single most important route by which the body permanently removes cholesterol. Every day, cholesterol 7α-hydroxylase converts a portion of your liver's cholesterol pool into primary bile acids — cholic acid and chenodeoxycholic acid — which are secreted into the gut, aid fat digestion, and are partially excreted in feces. The rate of this reaction sets how efficiently your body can clear excess cholesterol from circulation.

The rs1457043 variant is an intronic C-to-T substitution at position 58,497,880 on chromosome 8 (GRCh38), within the CYP7A1 gene on the minus strand. It does not change the CYP7A1 protein sequence but sits within a haplotype block that includes functionally important promoter and enhancer variants. Multiple population studies have identified rs1457043 as a tag SNP that co-segregates with CYP7A1 expression differences and associated lipid phenotypes.

The Mechanism

As an intron variant²² intron variant
a DNA change within a non-coding intervening sequence; can affect splicing, mRNA stability, local chromatin structure, or expression through regulatory elements without altering the protein sequence directly, rs1457043 does not directly alter CYP7A1 enzyme function. Its clinical relevance derives from linkage disequilibrium³³ linkage disequilibrium
the non-random association of alleles at two loci; nearby variants tend to be inherited together on the same chromosomal segment, so a tag SNP can predict the state of nearby functional variants with functional CYP7A1 regulatory variants in the same haplotype block.

The most functionally important variants in this region are rs3808607 (a promoter SNP, -203A>C) and rs9297994 (a downstream enhancer SNP), which together produce more than 100-fold variation in hepatic CYP7A1 mRNA expression⁴⁴ more than 100-fold variation in hepatic CYP7A1 mRNA expression
Li et al. showed these two SNPs interact through long-range chromatin contacts — their combined genotype, not either alone, predicts CYP7A1 expression, LDL levels, and statin response. rs1457043 recombines more frequently with these promoter variants than do other CYP7A1 SNPs, suggesting it tags a partially independent segment of the haplotype structure. When CYP7A1 activity is reduced, less cholesterol is converted to bile acids, leading to cholesterol accumulation in the liver, compensatory LDL receptor downregulation, and elevated circulating LDL-cholesterol.

The T allele (plus strand) is the major allele globally (~57%) and predominates in European (~59%) and Latino (~70%) populations. The C allele (GRCh38 reference) is in the minority globally but is common in African (~57%) and East Asian (~57%) populations. CC homozygotes — those with two C alleles — show the highest association with adverse lipid profiles in studied populations.

The Evidence

Subclinical atherosclerosis and LDL-cholesterol: The most specific evidence comes from a case-control study in Mexico⁵⁵ a case-control study in Mexico
Vargas-Alarcón et al. CYP7A1 gene polymorphisms are associated with increased LDL-cholesterol levels and the incidence of subclinical atherosclerosis. Biomol Biomed, 2025 comparing 416 patients with subclinical atherosclerosis (coronary artery calcium > 0) against 1,046 controls. Seven CYP7A1 polymorphisms were analyzed; rs1457043 homozygous minor allele carriers showed elevated incidence of subclinical atherosclerosis and higher LDL-cholesterol levels compared with other genotypes (p < 0.05). The LD analysis additionally showed that rs1457043 recombines more frequently than neighboring SNPs, indicating it partially captures independent haplotype variation.

Acute coronary syndrome and dyslipidemia: A companion study by the same group examined 1,317 ACS patients and 1,046 controls⁶⁶ examined 1,317 ACS patients and 1,046 controls
Vargas-Alarcón et al. Associations of CYP7A1 gene polymorphisms with risk of acute coronary syndrome, plasma cholesterol, and incidence of diabetes. Biomedicines, 2024 in a Mexican population. While five neighboring variants (rs9297994, rs10504255, rs8192870, rs2081687, rs10107182) reached significance for ACS risk and dyslipidemia, rs1457043 was included in the analysis as part of the broader CYP7A1 haplotype survey.

Drug-induced hepatotoxicity: In Chinese patients receiving anti-tuberculosis medications, rs1457043 CT (plus-strand) heterozygotes⁷⁷ rs1457043 CT (plus-strand) heterozygotes
Chen et al. CYP7A1, BAAT and UGT1A1 polymorphisms and susceptibility to anti-tuberculosis drug-induced hepatotoxicity. Int J Tuberc Lung Dis, 2016 had OR 2.05 (95% CI 1.18–3.15, p=0.014) for hepatotoxicity compared with CC homozygotes. This finding, combined with haplotype G-C or G-A combinations showing OR 2.40 (95% CI 1.62–3.57), suggests that CYP7A1 haplotype variation modifies hepatic bile acid flux in ways that can amplify drug toxicity. This is distinct from the lipid phenotype and likely reflects CYP7A1's role in liver bile acid homeostasis during pharmacological challenge.

CYP7A1 expression and statin response context: Research on nearby functional variants demonstrates that long-range chromatin interactions between rs3808607 and rs9297994⁸⁸ long-range chromatin interactions between rs3808607 and rs9297994
Li et al. Interactions Between Regulatory Variants in CYP7A1 Promoter and Enhancer Regions Regulate CYP7A1 Expression. Circ Genom Precis Med, 2018 produce the largest known range of CYP7A1 expression variation — over 100-fold. These expression differences correlate with LDL levels, coronary artery disease risk, and statin response, establishing the biological plausibility of rs1457043's haplotype-tagged effects.

Practical Actions

For CC homozygotes, the evidence suggests reduced efficiency of cholesterol-to-bile-acid conversion. The most direct interventions either support bile acid synthesis (plant sterols, soluble fiber) or monitor the downstream LDL consequences. Statins — which indirectly upregulate CYP7A1 expression through cholesterol depletion and SREBP signaling — remain the most evidence-based intervention for elevated LDL; however, the CYP7A1 haplotype context (via linked variants) may affect statin response magnitude and warrants LDL monitoring.

Plant sterols and stanols (2–3 g/day) compete with cholesterol for intestinal absorption, reducing the cholesterol pool that CYP7A1 must handle and independently lowering LDL by 5–15%. Soluble fiber (psyllium, oat beta-glucan) binds bile acids in the gut, reducing enterohepatic recirculation and compelling the liver to synthesize more bile acids from cholesterol — effectively compensating for reduced CYP7A1 activity.

Interactions

rs1457043 is in the same haplotype block as rs3808607 (the CYP7A1 promoter SNP, also called -203A>C or -204A>C in older literature), rs8192870, rs9297994 (downstream enhancer), and rs3824260. Because these variants partially recombine from each other, the combination matters: individuals carrying rs1457043 CC alongside risk haplotypes at rs3808607 and rs9297994 are likely to have the most severely reduced CYP7A1 expression. Conversely, individuals with rs1457043 CC but protective haplotypes at the functional promoter/enhancer SNPs may have attenuated phenotypic consequences. Compound actions across this haplotype block would require genotype data from the functional variants (rs3808607 and rs9297994) as well.

Before your body can make the long-chain omega-3 and omega-6 fats that drive anti-inflammatory signaling, membrane integrity, and brain function, it must clear a biochemical bottleneck: the first desaturation step. The enzyme responsible is delta-6 desaturase (D6D)¹¹ delta-6 desaturase (D6D)
also called Δ6-desaturase; encoded by FADS2 on chromosome 11q12.2; the rate-limiting first step in both the omega-3 and omega-6 PUFA elongation cascades. Without adequate D6D activity, short-chain essential fats from plant foods — alpha-linolenic acid (ALA) from flaxseed and linoleic acid (LA) from most vegetable oils — cannot enter the elongation pathway and accumulate as unused precursors while downstream products like EPA, DHA, and arachidonic acid remain scarce.

rs174568 is an intronic variant in FADS2 that sits within a tightly linked haplotype block spanning the entire FADS gene cluster. The T allele tags a regulatory state associated with reduced FADS2 expression and lower delta-6 desaturase activity. Because D6D operates upstream of delta-5 desaturase (encoded by FADS1), reduced FADS2 activity compresses both fatty acid pathways simultaneously.

The Mechanism

Delta-6 desaturase catalyzes two rate-limiting reactions: - Omega-6 pathway: linoleic acid (LA, 18:2) → gamma-linolenic acid (GLA, 18:3n-6) - Omega-3 pathway: alpha-linolenic acid (ALA, 18:3n-3) → stearidonic acid (SDA, 18:4n-3)

Both GLA and SDA are then elongated before undergoing a second desaturation by delta-5 desaturase (FADS1), ultimately yielding arachidonic acid (AA), EPA, and DHA. The T allele at rs174568 impairs this first step. The result is accumulation of LA and ALA with reduced production of all downstream long-chain products. Critically, because this is the upstream bottleneck, even a normally functioning FADS1 cannot compensate — there is less substrate for it to work with.

The intronic location of rs174568 suggests a regulatory effect on FADS2 transcription rather than a coding change in the enzyme itself. The FADS cluster contains multiple SNPs in high linkage disequilibrium that collectively modulate expression levels of FADS1, FADS2, and FADS3, likely through shared regulatory elements and allele-specific methylation patterns.

The Evidence

rs174568 was included in a study of the FADS gene cluster in 224 individuals from Tangier Island²² study of the FADS gene cluster in 224 individuals from Tangier Island
Mathias et al. 2010, FADS genetic variants and omega-6 PUFA metabolism in a homogeneous island population, J Lipid Res, a genetically isolated European founder population providing a clean signal for variant effects. rs174568 was one of eight SNPs in strong linkage disequilibrium showing the same pattern: the minor allele consistently associated with decreased omega-6 PUFAs including arachidonic acid, with increased DGLA (the immediate precursor to AA). Effect sizes for the strongest FADS1-activity ratio associations reached p = 5.8 × 10⁻⁷ to 1.7 × 10⁻⁸.

A Bayesian genetic analysis in 761 Alaskan Eskimos Voruganti et al. 2012, Variants in CPT1A, FADS1, and FADS2 are associated with higher levels of estimated plasma and erythrocyte delta-5 desaturases, Front Genet³³ Voruganti et al. 2012, Variants in CPT1A, FADS1, and FADS2 are associated with higher levels of estimated plasma and erythrocyte delta-5 desaturases, Front Genet identified rs174568 with posterior probability >0.8 for a functional effect on estimated delta desaturase activity. The finding was replicated in an independent Mexican American cohort, confirming cross-ancestry functional relevance.

The broader evidence for FADS cluster variants is substantial: a systematic review of 132 studies including ~500,000 participants⁴⁴ systematic review of 132 studies including ~500,000 participants
Visioli et al. 2026, Genetic modulation of omega-3 and omega-6 PUFA metabolism and health outcomes, Food Funct found that FADS1/FADS2 minor allele carriers show approximately 40–60% lower LC-PUFA conversion efficiency compared to common allele homozygotes, with 14 studies showing significant gene-by-diet interactions. At this effect size, plant-based omega-3 intake cannot reliably substitute for preformed EPA and DHA.

Practical Actions

For T allele carriers: plant-based omega-3 sources — flaxseed oil, chia seeds, walnuts — supply ALA, but the first conversion step (ALA → SDA via FADS2) is impaired. This makes preformed EPA and DHA from marine or algae sources the most reliable way to maintain adequate long-chain omega-3 status. TT homozygotes are most affected and should target 2–4 g combined EPA+DHA daily; CT heterozygotes benefit from 1–2 g daily.

For the omega-6 pathway, reduced GLA production means arachidonic acid synthesis from dietary linoleic acid is also impaired. While this sounds paradoxically protective (less AA = less pro-inflammatory eicosanoids), it also means cell membranes may be enriched with unconverted LA — a pattern associated with elevated triglycerides in some studies.

Monitoring triglyceride levels is warranted, particularly for TT homozygotes with diets high in refined omega-6 oils.

Interactions

rs174568 is in high linkage disequilibrium with multiple SNPs across the FADS1-FADS2-FADS3 cluster, including rs174537 (FADS1), rs174547 (FADS1), rs174575 (FADS2), and rs1535 (FADS2). Carriers of multiple minor alleles in this cluster experience compounding impairment at both the FADS2 (D6D) and FADS1 (D5D) steps — a complete blockade of the endogenous LC-PUFA synthesis pathway.

The functional consequence is similar to the neighboring FADS1 variants (rs174537, rs174547) already in the database, but operates at the earlier delta-6 step rather than delta-5, affecting a wider range of PUFA products. Both FADS2 and FADS1 minor allele carriers should prioritize preformed EPA/DHA over plant-based omega-3 sources.

AGER encodes RAGE (Receptor for Advanced Glycation End-Products), a pattern recognition receptor¹¹ pattern recognition receptor
A membrane protein that detects damage-associated molecular patterns including advanced glycation end-products, HMGB1, S100 proteins, and amyloid-beta — triggering NF-κB-mediated inflammation embedded in chromosome 6's Major Histocompatibility Complex (MHC) region. The MHC neighbourhood matters: RAGE sits among the densest concentration of immune-regulatory genes in the human genome, and genetic variation in this region shapes susceptibility to autoimmune disease in ways that extend beyond HLA alleles alone.

The rs17493811 variant lies in the 3′ downstream region of AGER and functions as a tag SNP²² tag SNP
A variant used as a proxy marker for a block of nearby genetic variation; it captures the effect of all correlated variants in the same linkage disequilibrium block, even if it is not itself the causal variant. Unlike the well-studied Gly82Ser missense variant (rs2070600), this SNP does not alter the RAGE protein directly — its influence is regulatory, likely affecting RAGE transcript levels, isoform ratios, or the balance between membrane-bound and soluble RAGE.

The Mechanism

RAGE sits at the convergence of metabolic and inflammatory stress. When advanced glycation end-products — formed from high blood glucose, high-heat cooking, or normal aging — bind RAGE, the receptor activates NF-κB and MAPK signaling cascades that drive chronic inflammatory gene expression. The soluble form of RAGE (sRAGE), which circulates as a decoy receptor scavenging AGEs before they reach membrane-bound RAGE, is a key modulator of this system.

The 3′ downstream region where rs17493811 sits can influence mRNA stability, alternative splicing, or the ratio of full-length to soluble RAGE isoforms. Critically, Salonen et al. (2014) found that rs17493811 was NOT significantly associated with sRAGE concentrations, distinguishing it from rs2070600 (which reduces sRAGE shedding by ~50%). This suggests rs17493811 may act through a separate mechanism — possibly modulating RAGE expression level, splicing of a less-studied isoform, or through linked causal variants in the 3′ regulatory region that affect autoimmune rather than metabolic RAGE signaling.

The Evidence

The primary evidence comes from Forbes et al. (2011)³³ Forbes et al. (2011)
Forbes JM et al. Receptor for advanced glycation end-products (RAGE) provides a link between genetic susceptibility and environmental factors in type 1 diabetes. Diabetologia, 2011, which analyzed 13 AGER tag SNPs in 3,624 Finnish individuals from the FinnDiane study and followed up associations in HLA-matched newborns from the Finnish Type 1 Diabetes Prediction and Prevention (DIPP) Study (n=373). Three AGER SNPs — rs2070600, rs9469089, and rs17493811 — predicted T1D risk independently of HLA-DR/DQ haplotype. For rs17493811, the odds ratio was 1.518 on a high-risk HLA background.

The biological context: RAGE activation is an established driver of beta-cell stress and islet inflammation. Dietary and endogenous AGEs accumulate in islet tissue, and RAGE signaling amplifies cytokine-mediated beta-cell destruction in T1D models. An AGER variant that alters RAGE expression or downstream signaling in islet cells — even modestly — could tip the balance between tolerance and autoimmune attack in genetically primed individuals.

A drop in circulating sRAGE has been documented at seroconversion to autoantibody positivity in children progressing toward T1D, and islet RAGE expression decreases over time in prediabetic mice, suggesting that RAGE dynamics in the pancreas are specifically perturbed in the autoimmune process. The rs17493811 variant may tag a haplotype that modulates this pancreatic RAGE regulation.

Practical Actions

For CG carriers, monitoring autoimmune-related biomarkers is the primary genotype-specific action. Because rs17493811 elevates T1D risk specifically in HLA high-risk contexts, the actionable response involves awareness of early autoimmune warning signs — particularly islet autoantibodies — in individuals with relevant HLA backgrounds or family history of type 1 diabetes.

The broader AGE-RAGE axis also connects to sleep quality: higher circulating AGE levels are independently associated with poor sleep, insomnia, and daytime sleepiness in population studies. Dietary AGE restriction (choosing moist-heat over high-heat cooking) reduces the AGE burden that drives RAGE signaling, offering a modifiable pathway relevant to anyone carrying risk variants in this gene.

Interactions

rs17493811 was studied alongside rs2070600 (Gly82Ser) and rs9469089 in the Forbes 2011 and Salonen 2014 studies. The three variants appear to act through distinct mechanisms: rs2070600 reduces sRAGE shedding (the most characterized functional effect), while rs17493811 and rs9469089 may affect RAGE expression or autoimmune-specific regulatory pathways. Haplotype analyses suggest that the combined effect of multiple AGER variants exceeds any single SNP's contribution. Individuals carrying rs17493811 G alongside rs2070600 T represent a compound risk scenario that would warrant more aggressive monitoring than either variant alone.

Type I collagen is the most abundant protein in bone, accounting for roughly 90% of the organic bone matrix¹¹ organic bone matrix
The protein framework that mineralizes to become hard bone. The COL1A1 gene encodes the alpha-1 chain, two of which combine with one alpha-2 chain to form the collagen triple helix. Deep within the first intron of COL1A1 lies a binding site for Sp1²² Sp1
A transcription factor that regulates collagen gene expression, a transcription factor that controls how much collagen your cells produce. The rs1800012 polymorphism — a single G-to-T change — alters this binding site, and that small change has rippled through decades of osteoporosis research.

The Mechanism

The T allele increases Sp1 binding affinity, leading to approximately three-fold higher abundance of transcripts from the T allele compared to the G allele in heterozygotes.

This might sound beneficial — more collagen transcription should mean stronger bones — but the reality is more complex.

Osteoblasts from individuals with the T allele produce an altered ratio of alpha-1 to alpha-2 collagen chains.

This disruption in collagen stoichiometry reduces the yield strength of bone , making it more brittle even when bone mineral density appears normal.

The polymorphism sits in a regulatory region³³ regulatory region
Intron 1 of COL1A1, previously shown to be critical for collagen transcription control that fine-tunes collagen production throughout life. During periods of high bone turnover — adolescence, pregnancy, menopause — the effects become particularly apparent.

The Evidence

The association between rs1800012 and bone health is one of the most thoroughly studied in skeletal genetics.

A meta-analysis of nearly 7,000 subjects found that heterozygotes (GT) had 1.26 times the odds of any fracture, while TT homozygotes had 1.78 times the odds, with the effect driven primarily by vertebral fractures (OR 1.37 for GT, 2.48 for TT).

Large-scale bone density studies⁴⁴ Large-scale bone density studies
The GENOMOS consortium analyzed over 20,000 participants across Europe confirmed modest but consistent reductions in BMD.

The TT genotype showed 21 mg/cm² lower BMD at the lumbar spine and 25 mg/cm² lower at the femoral neck compared to GG.

While these differences may seem small, they compound over decades.

The effect is sexually dimorphic and age-dependent.

Girls with the TT genotype have significantly lower BMD Z-scores before puberty completion, but this association attenuates after puberty.

The data suggest rs1800012 principally affects female bone density during periods of high turnover

— puberty and postmenopause — when the collagen scaffolding is being rapidly remodeled.

Interestingly, the same variant that increases osteoporosis risk appears protective for certain soft tissue injuries.

A meta-analysis found the rare TT genotype associated with reduced risk of sports-related tendon and ligament injuries (OR 0.17), particularly ACL tears, suggesting the altered collagen may be more flexible and resistant to acute trauma.

Practical Implications

If you carry one or two T alleles, your bones require more vigilant care, especially during high-turnover periods. Adequate calcium and vitamin D are non-negotiable — they're the raw materials your body uses to mineralize the collagen framework, and suboptimal intake compounds the structural disadvantage of altered collagen quality.

Calcium and vitamin D supplementation has been shown to suppress bone turnover, increase bone mass, and even reduce fracture incidence, with benefits observed even in young adults.

For TT homozygotes, consider maintaining 25-hydroxyvitamin D levels toward the higher end of the normal range (40-60 ng/mL) and ensuring calcium intake meets or exceeds recommendations (1,000-1,200 mg daily for adults).

Weight-bearing exercise⁵⁵ Weight-bearing exercise
Resistance training and impact activities that stimulate bone formation is equally critical, as mechanical stress signals osteoblasts to strengthen bone. However, the protective effect against soft tissue injuries suggests TT carriers may have a biomechanical advantage in certain athletic contexts — though bone fragility remains the dominant concern.

Postmenopausal women with the TT genotype should discuss baseline bone density screening with their physician, as they may benefit from earlier monitoring and proactive intervention if BMD declines.

Interactions

The rs1800012 polymorphism exists within a haplotype structure at the COL1A1 locus.

It's in strong linkage disequilibrium with rs1107946 and rs2412298, and these haplotypes show bidirectional regulation of BMD.

Individuals carrying multiple risk alleles across these linked variants may experience compounded effects on bone metabolism.

Beyond COL1A1 itself, bone health is influenced by variants in genes controlling calcium absorption (VDR, vitamin D receptor), bone resorption (TNFRSF11B/osteoprotegerin), and the RANK-RANKL-OPG pathway⁶⁶ RANK-RANKL-OPG pathway
The master regulatory system controlling osteoclast activity. While no formal compound implications have been established for rs1800012 plus other bone health SNPs, individuals with multiple genetic risk factors should be particularly proactive about bone-protective lifestyle measures.

Transforming growth factor beta 1 (TGF-β1) is one of the most versatile signaling molecules in the cardiovascular system — it can stabilize arterial plaques, suppress excessive inflammation, and regulate the repair of damaged heart muscle. But when TGF-β1 production tips too high or its signaling becomes dysregulated, the same molecule drives fibrosis, atherosclerosis progression, and myocardial remodeling after injury. The rs1800471 variant (R25P, Arg25Pro) sits in the signal peptide of the TGFB1 gene on chromosome 19q13¹¹ chromosome 19q13
NC_000019.10:g.41352971C>G; TGFB1 encodes the inactive pre-pro-protein, cleaved to the active dimer, altering how efficiently the protein is threaded into the endoplasmic reticulum and ultimately secreted. The minor G allele (Pro25 on plus strand, coding C at position 915) influences TGF-β1 levels and has been linked to cardiovascular outcomes in multiple cohorts — though the direction and magnitude of risk are modest and population-dependent.

The Mechanism

The signal peptide is the N-terminal zip code that directs newly synthesized proteins into the secretory pathway. The Arg25Pro substitution changes a positively charged arginine to a neutral proline²² changes a positively charged arginine to a neutral proline
Proline introduces a rigid kink in the peptide backbone, potentially disrupting signal-peptide secondary structure and slowing translocation in this critical region. Functional studies show that different haplotypes formed by the codon 10 (rs1800470, L10P) and codon 25 (rs1800471, R25P) variants stratify individuals into high, intermediate, and low TGF-β1 producers³³ high, intermediate, and low TGF-β1 producers
Leukocyte in-vitro assays measuring TGF-β1 in cell supernatants after stimulation classify genotype combinations into production categories. The GG coding genotype (homozygous Arg25, corresponding to plus-strand CC) is most commonly associated with highest TGF-β1 secretion capacity; the heterozygous state produces intermediate levels.

TGF-β1 has a dual and context-dependent role in the vasculature. At physiological levels it stabilizes atherosclerotic plaques⁴⁴ stabilizes atherosclerotic plaques
TGF-β1 promotes smooth muscle cell contractility and fibrous cap formation, reducing plaque vulnerability to rupture and suppresses macrophage-mediated inflammation. At chronically elevated levels, it drives myocardial and vascular fibrosis⁵⁵ drives myocardial and vascular fibrosis
Activates cardiac fibroblasts, increases collagen deposition, promotes atrial and ventricular remodeling — contributing to arrhythmia susceptibility, reduced cardiac compliance, and post-MI scarring.

The Evidence

The most comprehensive genetic evidence comes from a 2012 meta-analysis of 5 studies⁶⁶ 2012 meta-analysis of 5 studies
Qu et al., BMC Medical Genetics, 14,452 participants total that found minor allele (coding C, plus-strand G) carriers had a pooled OR of 1.16 (95% CI 1.02–1.32) for coronary heart disease. The heterozygous GC (coding, plus-strand CG) genotype conferred OR 1.15 (1.01–1.31) versus homozygous major allele carriers. However, statistical significance disappeared after Egger's test correction for publication bias, highlighting the modest and population-heterogeneous nature of the association.

Orthogonal evidence from fibrotic and electrophysiological studies is more consistent. A study of essential hypertensive patients⁷⁷ study of essential hypertensive patients
Chen et al., Journal of Biomedical Science 2010, n=259 found the GG coding genotype was significantly overrepresented in patients with both hypertension and atrial fibrillation versus hypertension alone (P=0.009). GG coding carriers had the highest serum TGF-β1 levels among AF-positive subjects, with a 3.09-fold elevated AF risk in this context. Since atrial fibrosis is the primary substrate for atrial fibrillation, this provides a mechanistic link from the genotype through TGF-β1 to cardiac remodeling.

A Russian cohort study of MI patients⁸⁸ Russian cohort study of MI patients
Contribution of TGFB1 to MI susceptibility, PMC3408705 found the GG coding genotype (high producer) significantly enriched in MI cases versus controls (OR 1.76, 95% CI 1.05–2.97, P=0.048). A study of TGFB1 and coronary heart disease with angiographic confirmation⁹⁹ TGFB1 and coronary heart disease with angiographic confirmation
Lamblin et al., PMID 16543493 similarly linked codon 25 variants to MI in patients with confirmed CHD. The Rotterdam Study (n=5,972)¹⁰¹⁰ Rotterdam Study (n=5,972)
Verhoeven et al., Thrombosis and Haemostasis 2006 found no association with MI, illustrating the population-specific heterogeneity that characterizes this SNP.

Additional context: rs1800471 has been associated with hypertension and CKD progression¹¹¹¹ hypertension and CKD progression
Polish cohort, Archives of Medical Science 2013, consistent with the broader role of TGF-β1 in cardiovascular-renal fibrotic pathways.

Practical Actions

The cardiovascular implications of rs1800471 are primarily mediated through TGF-β1's effect on vascular inflammation and fibrosis. Carrying the minor G allele (plus strand) is associated with lower TGF-β1 production, and the heterozygous state shows modest CHD risk in aggregate analyses. Monitoring for early signs of cardiovascular disease and specific management of fibrosis-related risk factors (blood pressure, myocardial stiffness) are most relevant to this variant's biology.

Interactions

rs1800471 (codon 25) and rs1800470 (codon 10, L10P) are the two primary coding variants in the TGFB1 signal peptide. Together they form haplotypes that stratify TGF-β1 production capacity. The codon 10 high-producer T allele (rs1800470) and codon 25 G coding allele (rs1800471) combine into distinct HIGH, INTERMEDIATE, and LOW producer haplotypes. Carriers of both high-producer alleles across both codons show the strongest elevation in TGF-β1 secretion and likely the highest cumulative cardiovascular risk through fibrotic pathways. The rs1800469 promoter variant (-509 C/T) provides additional regulation of TGF-β1 transcription and should be interpreted alongside the coding variants.

FOXO3 is one of only two human genes — along with APOE — whose longevity associations have been consistently replicated across multiple independent populations and ancestries. The first FOXO3 signal, rs2802292¹¹ rs2802292
the well-characterized HSF1-binding enhancer variant in intron 2, has been studied intensively since 2008. But FOXO3's longevity architecture is more complex: rs1935949 tags a second, independent haplotype block spanning 121 kilobases of FOXO3 intron 3 that independently contributes to centenarian enrichment through a distinct regulatory mechanism.

Pawlikowska et al. 2009²² Pawlikowska et al. 2009
Association of common genetic variation in the insulin/IGF1 signaling pathway with human longevity. Aging Cell. 2009 identified rs1935949 among longevity-associated variants across three Caucasian cohorts — the Study of Osteoporotic Fractures, the Cardiovascular Health Study, and Ashkenazi Jewish Centenarians — finding a significant longevity association in women (OR = 1.35, 95% CI 1.15–1.57, adjusted p = 0.0093).

The Mechanism

rs1935949 sits in intron 3 of FOXO3, approximately 1.7 kilobase-pairs from an intron-exon boundary, and is in strong linkage disequilibrium (r² = 0.96) with rs4946935 — the functionally characterized variant in the same haplotype block. Flachsbart et al. 2017³³ Flachsbart et al. 2017
Identification and characterization of two functional variants in the human longevity gene FOXO3. Nat Commun. 2017 demonstrated that the longevity allele of rs4946935 creates an allele-dependent binding site for serum response factor (SRF) — a transcription factor distinct from the heat shock factor 1 (HSF1) that binds the rs2802292 site. In luciferase reporter assays, the longevity alleles at rs4946935 (and by proxy, rs1935949) show substantial enhancer activity that is specifically reversed by IGF-1 treatment.

This IGF-1 reversibility is mechanistically significant. The insulin/IGF-1 signaling (IIS) pathway⁴⁴ insulin/IGF-1 signaling (IIS) pathway
the PI3K-AKT cascade that phosphorylates and excludes FOXO3 from the nucleus is the primary evolutionary brake on FOXO3 activity: high IGF-1 levels drive AKT activation, which phosphorylates FOXO3 and traps it in the cytoplasm, preventing it from activating stress-response and longevity genes. The longevity allele at rs1935949's haplotype creates an enhancer that is most active when IGF-1 is low — exactly the dietary and metabolic condition under which FOXO3's protective functions matter most. This explains why the variant was first identified in a study of IGF-1 signaling pathway genetics and why its effects are magnified by caloric restriction and fasting contexts.

An eQTL database search confirms that the longevity alleles associated with the rs1935949/rs4946935 haplotype block are associated with higher FOXO3 mRNA expression across multiple human tissues, consistent with the enhancer model. The haplotype containing rs1935949 (haplotype block 1, alongside rs13217795, rs2764264, rs9400239, and rs9486902, D'>0.86 spanning 121 kb) is structurally distinct⁵⁵ structurally distinct
the haplotype blocks were identified by LD analysis across 12 FOXO3 SNPs from the block containing rs2802292, allowing independent additive effects on longevity.

The Evidence

Bao et al. 2014⁶⁶ Bao et al. 2014
Association between FOXO3A gene polymorphisms and human longevity: a meta-analysis. Asian J Androl. 2014 pooled five of its eleven studies that genotyped rs1935949, encompassing 1,435 cases and 2,098 controls, finding significant overall longevity association (OR = 1.14, 95% CI 1.01–1.27). Gender-stratified results suggested the overall association was not driven primarily by females in this cohort, though the sex-specific picture is complex and differs across studies.

The largest replication effort comes from Bae et al. 2018⁷⁷ Bae et al. 2018
Effects of FOXO3 polymorphisms on survival to extreme longevity in four centenarian studies. J Gerontol A Biol Sci Med Sci. 2018, which analyzed 2,072 cases and 6,194 controls across the Long Life Family Study, New England Centenarian Study, Southern Italian Centenarian Study, and Longevity Genes Project. rs1935949 showed a meta-analysis beta of 0.18 (SE 0.044, p = 6.60×10⁻⁵), corresponding to approximately OR = 1.20 for extreme longevity (defined as surviving to the oldest 1 percentile of the 1900 U.S. birth cohort — ≥96 years for males, ≥100 for females). Centenarian enrichment of the protective A allele was observed in all four cohorts, though effect sizes varied.

Evidence is strongest in Caucasian populations. Studies in Chinese Han populations did not replicate the rs1935949 association, consistent with population-specific LD patterns and potentially different regulatory architectures across ancestries.

Practical Implications

The IGF-1-reversible nature of this haplotype's regulatory effect suggests a dietary angle that is more explicit than for rs2802292. Dietary interventions that lower circulating IGF-1 — particularly plant-protein-predominant diets and periodic fasting — reduce IGF-1-mediated suppression of FOXO3 at this enhancer. Caloric restriction extending maximum lifespan in model organisms is mechanistically connected to reduced IIS signaling and consequent FOXO3 activation; the rs1935949 haplotype may amplify this response.

The additive architecture of FOXO3 longevity signals is worth appreciating. Individuals who carry protective alleles at both rs1935949 and rs2802292 benefit from independent contributions to FOXO3 expression through distinct transcription factor binding sites (SRF at the rs4946935/rs1935949 haplotype; HSF1 at rs2802292). The two mechanisms respond to different cellular stresses — nutrient status for the IGF-1-sensitive haplotype, heat shock and oxidative stress for the HSF1 site — making them genuinely complementary.

Interactions

rs1935949 and rs2802292 are in different haplotype blocks across FOXO3 and have independent longevity effects. Individuals carrying protective alleles at both loci likely experience additive longevity benefit through distinct molecular mechanisms (SRF-mediated nutrient-sensing regulation vs. HSF1-mediated stress response regulation). A compound action is worth considering for individuals carrying beneficial alleles at both rsids, as the combined message — targeting both IGF-1 reduction and stress-response activation — is more specific than either alone.

rs4946935 (r² = 0.96 with rs1935949) is the functional proxy variant for the enhancer mechanism; individuals who have both in their genome data will likely have concordant results. rs13217795, also in haplotype block 1, has been separately shown to regulate an alternative FOXO3 promoter (FOXO3-TR isoform expression), adding another regulatory dimension to the same haplotype block.